A

Akero Therapeutics
D

AKRO

51.760
USD
-0.13
(-0.24%)
مغلق
حجم التداول
22,463
الربح لكل سهم
-4
العائد الربحي
-
P/E
-14
حجم السوق
4,126,181,423
أصول ذات صلة
SUSHIUSD
SUSHIUSD
0.01635
(2.77%)
0.60550 USD
AAVEUSD
AAVEUSD
12.96
(4.74%)
286.51 USD
C
COMP
0.10500
(1.66%)
6.43000 USD
S
SNX
0.880
(0.63%)
140.140 USD
المزيد
الأخبار المقالات

العنوان: Akero Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.